Acceleron Appoints Jay T. Backstrom, M.D., M.P.H., to Newly Created Role as Head of Research and Development
09 Diciembre 2019 - 6:30AM
Business Wire
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical
company in the discovery and development of TGF-beta superfamily
therapeutics to treat serious and rare diseases, announced today
the appointment of Jay T. Backstrom, M.D., M.P.H., as Executive
Vice President, Research and Development (R&D). Dr. Backstrom
joins Acceleron from Celgene Corporation, where he most recently
served as Chief Medical Officer (CMO).
“During his time at Celgene, I personally found Jay to be an
outstanding partner and collaborator, and I couldn’t be more
thrilled to be working alongside him,” said Habib Dable, President
and Chief Executive Officer of Acceleron. “He was instrumental in
helping us bring REBLOZYL®, Acceleron’s first approved medicine, to
patients, so we’re truly fortunate to have someone with Jay’s depth
and breadth of experience to lead our corporate R&D strategy as
we usher Acceleron into an exciting new phase.”
Dr. Backstrom brings to Acceleron nearly three decades of global
clinical and regulatory experience in preparing and executing
development strategies leading to regulatory approvals across a
broad range of therapeutic areas, including hematologic, oncologic,
immunologic, cardiovascular, and pulmonary diseases.
Dr. Backstrom joined Celgene in 2008 as Vice President, Clinical
R&D with a focus in hematology/oncology, later advancing to the
position of CMO and Head of Regulatory Affairs. Prior to Celgene,
he served as Vice President, Global Medical Affairs and Safety at
Pharmion. Dr. Backstrom began his career in industry in 1990 at
Marion Merrell Dow and continued as part of its successor companies
including Hoechst Marion Roussel, where he held positions in
Clinical Research and Global Drug Surveillance and
Pharmacoepidemiology. He also spent nearly three years at Quintiles
in Medical and Scientific Services, including Therapeutic Head,
Cardiovascular, Respiratory and Critical Care where he oversaw
extensive clinical work across a variety of cardiovascular and
pulmonary diseases.
Dr. Backstrom served as staff physician and Medical Director of
the Samuel U. Rodgers Community Health Center in Kansas City,
Missouri. Dr. Backstrom holds an M.D. from Temple University School
of Medicine and received post-graduate training in Internal
Medicine at Temple University Hospital. He also earned a Master’s
in Public Health from Saint Louis University School of Public
Health.
“It’s a privilege to be joining a company I know so well and
have long admired,” said Dr. Backstrom. “I’ve witnessed first-hand
the impact Acceleron’s expertise in TGF-beta superfamily biology
could have in the hematology space, and so I now look forward to
helping the Company further develop and fully realize the potential
of its pipeline in additional therapeutic areas.”
About Acceleron
Acceleron is a biopharmaceutical company dedicated to the
discovery, development, and commercialization of therapeutics to
treat serious and rare diseases. The Company's leadership in the
understanding of TGF-beta superfamily biology and protein
engineering generates innovative compounds that engage the body's
ability to regulate cellular growth and repair.
Acceleron focuses its research and development efforts in
hematologic, neuromuscular, and pulmonary diseases. In hematology,
the Company and its global collaboration partner, Bristol-Myers
Squibb, are co-promoting newly approved REBLOZYL®
(luspatercept-aamt), the first and only approved erythroid
maturation agent, in the United States and are developing
luspatercept for the treatment of chronic anemia in myelodysplastic
syndromes and myelofibrosis. Acceleron is also advancing its
neuromuscular program with ACE-083, a locally-acting Myostatin+
agent in Phase 2 development in Charcot-Marie-Tooth disease and is
conducting a Phase 2 pulmonary program with sotatercept in
pulmonary arterial hypertension.
For more information, please visit www.acceleronpharma.com.
Follow Acceleron on Social Media: @AcceleronPharma and
LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191209005252/en/
Acceleron Pharma Inc.
Investors: Todd James, IRC, (617) 649-9393 Vice President,
Investor Relations and Corporate Communications
Ed Joyce, (617) 649-9242 Director, Investor Relations
Media: Matt Fearer, (617) 301-9557 Director, Corporate
Communications
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024